Pliant Therapeutics gets FDA Fast Track for PLN-101095 plus pembrolizumab
Pliant Therapeutics (PLRX) receives FDA Fast Track designation for PLN-101095 when used in combination with pembrolizumab to treat ICI-refractory solid tumors.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.